Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Azurity Drug Patent Portfolio

Azurity owns 44 orange book drugs protected by 242 US patents with Rilutek having the least patent protection, holding only 1 patent. And Contrave with maximum patent protection, holding 22 patents. Given below is the list of Azurity's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12290529 Methods of administering safe colon cleansing compositions 02 Aug, 2044
Active
US12239659 Methods of administering safe colon cleansing compositions 14 Jun, 2044
Active
US12433914 Methods Of Administering Safe Colon Cleansing Compositions 14 Jun, 2044
Active
US12594298 Methods Of Administering Safe Colon Cleansing Compositions 14 Jun, 2044
Active
US11707450 29 Jul, 2042
Active
US11844784 Stable pharmaceutical compositions of bendamustine 29 Jul, 2042
Active
US12208086 Stable pharmaceutical compositions of bendamustine 29 Jul, 2042
Active
US12419867 Stable Pharmaceutical Compositions Of Bendamustine 29 Jul, 2042
Active
US12233049 Stable Pharmaceutical Compositions Of Clonidine 15 Jul, 2042
Active
US12440474 Stable Pharmaceutical Compositions Of Clonidine 15 Jul, 2042
Active
US12263176 Pharmaceutical liquid compositions of meloxicam 31 Jul, 2041
Active
US11944621 Oral gliptin compositions and method for preparation thereof 23 Oct, 2040
Active
US12295953 Oral gliptin compositions and method for preparation thereof 23 Oct, 2040
Active
US11576878 Oral solutions comprising lisdexamfetamine salts 30 Aug, 2040
Active
US11433046 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
Active
US11633374 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
Active
US11826343 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
Active
US11911362 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
Active
US12290503 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
Active
US12433859 Oral Solutions Comprising Lisdexamfetamine Salts 16 Apr, 2040
Active
US12582620 Oral Solutions Comprising Lisdexamfetamine Salts 16 Apr, 2040
Active
US11771686 Compositions and kits for omeprazole suspension 01 Mar, 2040
Active
US10874671 Pharmaceutical compositions of nilotinib 18 Feb, 2040
Active
US11793809 Pharmaceutical compositions of nilotinib 18 Feb, 2040
Active
US12403140 Pharmaceutical Compositions Of Nilotinib 18 Feb, 2040
Active
US12629369 Pharmaceutical Compositions Of Nilotinib 18 Feb, 2040
Active
US11931455 Pharmaceutical suspension for oral dosage 16 Aug, 2039
Active
US12097284 Mycophenolate oral suspension 16 Aug, 2039
Active
US12097285 Mycophenolate oral suspension 16 Aug, 2039
Active
US12194143 Mycophenolate oral suspension 16 Aug, 2039
Active
US12226526 Mycophenolate oral suspension 16 Aug, 2039
Active
US10751333 Compositions and kits for omeprazole suspension 16 Jul, 2039
Active
US11103492 Compositions and kits for omeprazole suspension 16 Jul, 2039
Active
US11633478 Compositions and kits for Omeprazole suspension 16 Jul, 2039
Active
US11911473 Compositions and kits for omeprazole suspension 16 Jul, 2039
Active
US12042539 Compositions and kits for Omeprazole suspension 16 Jul, 2039
Active
US12329752 Compositions and kits for omeprazole suspension 16 Jul, 2039
Active
US12440566 Compositions And Kits For Omeprazole Suspension 16 Jul, 2039
Active
US10799453 Amlodipine formulations 11 Apr, 2039
Active
US11311554 Pharmaceutical compositions of testosterone 25 Mar, 2039
Active
US11642355 Pharmaceutical compositions of testosterone 25 Mar, 2039
Active
US12138271 Pharmaceutical compositions of testosterone 25 Mar, 2039
Active
US10456354 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate 25 Oct, 2038
Active
US11110054 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate 25 Oct, 2038
Active
US11938217 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate 25 Oct, 2038
Active
US12151020 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate 25 Oct, 2038
Active
US12383491 Ready-To-Use Injectable Pharmaceutical Compositions Comprising Neostigmine And Glycopyrrolate 25 Oct, 2038
Active
US11478456 Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof 18 Aug, 2038
Active
US11529333 Oral pharmaceutical composition comprising zonisamide and process of preparation thereof 18 Aug, 2038
Active
US12491179 Oral Pharmaceutical Composition Comprising Zonisamide And Process Of Preparation Thereof 18 Aug, 2038
Active
US12685723 18 Aug, 2038
Active
US10342787 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
Active
US10576070 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
Active
US11207306 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
Active
US11413277 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
Active
US11517563 Liquid nimodipine compositions 16 Apr, 2038
Active
US11759457 Liquid nimodipine compositions 16 Apr, 2038
Active
US11806338 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
Active
US12186308 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
Active
US10322117 Compositions for the treatment of hypertension 23 Jan, 2038
Active
US10799487 Compositions for the treatment of hypertension 23 Jan, 2038
Active
US12465599 Compositions For The Treatment Of Hypertension 23 Jan, 2038
Active
US12673047 Compositions For The Treatment Of Hypertension 23 Jan, 2038
Active
US10695329 Amlodipine formulations 16 Oct, 2037
Active
US10894039 Amlodipine formulations 06 Oct, 2037
Active
US10952998 Amlodipine formulations 06 Oct, 2037
Active
US10959991 Amlodipine formulations 06 Oct, 2037
Active
US11364230 Amlodipine formulations 06 Oct, 2037
Active
US11471409 Amlodipine formulations 06 Oct, 2037
Active
US11484498 Amlodipine formulations 06 Oct, 2037
Active
US11701326 Amlodipine formulations 06 Oct, 2037
Active
US11918685 Amlodipine formulations 06 Oct, 2037
Active
US12053461 Amlodipine formulations 06 Oct, 2037
Active
US12336984 Amlodipine formulations 06 Oct, 2037
Active
US12383498 Amlodipine Formulations 06 Oct, 2037
Active
US11324696 Suspensions and diluents for metronidazole and baclofen 29 Sep, 2037
Active
US11446246 Suspensions and diluents for metronidazole and baclofen 08 Sep, 2037
Active
US10143656 Solid oral sulfate salt formulations for cleaning a colon and methods of using same 04 Aug, 2037
Active
US11033498 Solid oral sulfate salt formulations for cleaning a colon and methods of using same 04 Aug, 2037
Active
US11382864 Solid oral sulfate salt formulations for cleansing a colon and methods of using same 04 Aug, 2037
Active
US11638697 Solid oral sulfate salt formulations for cleaning a colon and methods of using same 04 Aug, 2037
Active
US10441554 Oral amphetamine composition 10 Mar, 2037
Active
US11160772 Oral amphetamine composition 10 Mar, 2037
Active
US11896562 Oral amphetamine composition 10 Mar, 2037
Active
US10039745 Enalapril formulations 25 Mar, 2036
Active
US10154987 Enalapril formulations 25 Mar, 2036
Active
US10772868 Enalapril formulations 25 Mar, 2036
Active
US10786482 Enalapril formulations 25 Mar, 2036
Active
US11040023 Enalapril formulations 25 Mar, 2036
Active
US11141405 Enalapril formulations 25 Mar, 2036
Active
US11173141 Enalapril formulations 25 Mar, 2036
Active
US9669008 Enalapril formulations 25 Mar, 2036
Active
US9808442 Enalapril formulations 25 Mar, 2036
Active
US10039800 Lisinopril formulations 06 Nov, 2035
Active
US10265370 Lisinopril formulations 06 Nov, 2035
Active
US10406199 Lisinopril formulations 06 Nov, 2035
Active
US10940177 Lisinopril formulations 06 Nov, 2035
Active
US11179434 Lisinopril formulations 06 Nov, 2035
Active
US11771733 Lisinopril formulations 06 Nov, 2035
Active
US12128083 Lisinopril formulations 06 Nov, 2035
Active
US12186360 Lisinopril formulations 06 Nov, 2035
Active
US12433931 Lisinopril Formulations 06 Nov, 2035
Active
US9463183 Lisinopril formulations 06 Nov, 2035
Active
US9616096 Lisinopril formulations 06 Nov, 2035
Active
US9814751 Lisinopril formulations 06 Nov, 2035
Active
US9724297 Sotalol compositions and uses of the same 31 Aug, 2035
Active
US10493028 Composition and method for vancomycin oral liquid 13 Mar, 2035
Active
US10688046 Composition and method for vancomycin oral liquid 13 Mar, 2035
Active
US10959946 Composition and method for vancomycin oral liquid 13 Mar, 2035
Active
US10959947 Composition and method for vancomycin oral liquid 13 Mar, 2035
Active
US10959948 Composition and method for vancomycin oral liquid 13 Mar, 2035
Active
US10959949 Composition and method for vancomycin oral liquid 13 Mar, 2035
Active
US11638692 Composition and method for vancomycin oral liquid 13 Mar, 2035
Active
US11850222 Sotalol compositions and uses of the same 19 Nov, 2034
Active
US10076614 Nasal delivery devices 20 Oct, 2034
Active
US10231964 Compositions and methods for weight loss in at risk patient populations 02 Jul, 2034
Active
US10828294 Compositions and methods for weight loss in at risk patient populations 02 Jul, 2034
Active
US10835527 Compositions and methods for reducing major adverse cardiovascular events 02 Jul, 2034
Active
US11998542 Compositions and methods for reducing major adverse cardiovascular events 02 Jul, 2034
Active
US10206895 Sotalol compositions and uses of the same 01 Apr, 2034
Active
US11013703 Sotalol compositions and uses of the same 01 Apr, 2034
Active
US12290495 Sotalol compositions and uses of the same 01 Apr, 2034
Active
US10478574 Nasal administration 04 Nov, 2033
Active
US9633575 Methods of treating overweight and obesity 25 Jun, 2033
Active
US10403170 Methods of treating overweight and obesity 05 Jun, 2033
Active
US11139056 Methods of treating overweight and obesity 05 Jun, 2033
Active
US10231927 Methotrexate composition 02 Jan, 2033
Active
US10610485 Methotrexate composition 02 Jan, 2033
Active
US11116724 Methotrexate composition 02 Jan, 2033
Active
US11969503 Methotrexate composition 02 Jan, 2033
Active
US12396947 Methotrexate Composition 02 Jan, 2033
Active
US9259427 Methotrexate composition 02 Jan, 2033
Active
US9855215 Methotrexate composition 02 Jan, 2033
Active
US8568747 Enalapril compositions 06 Nov, 2032
Active
US8778366 Enalapril compositions 06 Nov, 2032
Active
US9855214 Enalapril compositions 06 Nov, 2032
Active
US9968553 Enalapril compositions 06 Nov, 2032
Active
US9248123 Methods of providing weight loss therapy in patients with major depression 13 Jan, 2032
Active
US9387249 Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone 01 Jul, 2031
Active
US11033543 Methods of providing weight loss therapy in patients with major depression 10 Jan, 2031
Active
US8978647 Nasal delivery 06 Dec, 2030
Active
US9649456 Nasal administration 21 Oct, 2030
Active
US8899229 Powder delivery devices 18 Aug, 2030
Active
US9169238 Solid pharmaceutical composition 04 Feb, 2030
Active
US8916195 Sustained release formulation of naltrexone 02 Feb, 2030
Active
US8550073 Nasal delivery 22 Oct, 2029
Active
US10076615 Nasal delivery 30 Jul, 2029
Active
US10166181 Slow release pharmaceutical composition made of microgranules 30 Jun, 2029
Active
US8795725 GABA analog prodrug sustained release oral dosage forms 10 Jun, 2029
Active
US11324741 Methods for treating visceral fat conditions 29 May, 2029
Active
US10085974 Dosage and formulation 13 Mar, 2029
Active
US11000517 Dosage and formulation 13 Mar, 2029
Active
US8088786 Layered pharmaceutical formulations 03 Feb, 2029
Active
US10722667 Nasal administration 30 Dec, 2028
Active
US8875704 Nasal administration 07 Apr, 2028
Active
US9066936 Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent 26 Mar, 2028
Active
US8371292 Use of ciclesonide for the treatment of respiratory diseases 01 Feb, 2028
Active
US10398859 Nasal delivery devices 19 Dec, 2027
Active
US10307376 Methods for administering weight loss medications 08 Nov, 2027
Active
US12048769 Methods for administering weight loss medications 08 Nov, 2027
Active
US8318788 Layered pharmaceutical formulations 08 Nov, 2027
Active
US8722085 Methods for administering weight loss medications 08 Nov, 2027
Active
US9125868 Methods for administering weight loss medications 08 Nov, 2027
Active
US9107837 Sustained release formulation of naltrexone 04 Jun, 2027
Active
US8051851 Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler 22 Apr, 2027
Active
US10124132 Nasal delivery 06 Mar, 2027
Active
US8026279 Crystalline form of γ-aminobutyric acid analog 10 Nov, 2026
Active
US8114909 Treating or preventing restless legs syndrome using prodrugs of GABA analogs 11 Apr, 2026 Expired
US7332183 Multilayer dosage forms containing NSAIDs and triptans 02 Apr, 2026 Expired
US11571531 Powder delivery devices 23 Feb, 2026 Expired
US7332183 Multilayer dosage forms containing NSAIDs and triptans 02 Oct, 2025 Expired
US8590530 Nasal delivery devices 15 Sep, 2025 Expired
US9108015 Nasal delivery devices 15 Sep, 2025 Expired
US7975690 Nasal devices 18 Aug, 2025 Expired
US7157584 Benzimidazole derivative and use thereof 22 May, 2025 Expired
US6818787 Prodrugs of GABA analogs, compositions and uses thereof 06 Apr, 2025 Expired
US7375111 Compositions for affecting weight loss 26 Mar, 2025 Expired
USRE46417 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands 10 Feb, 2025 Expired
US8686034 Crystalline form of γ-aminobutyric acid analog 24 Jan, 2025 Expired
US7572920 Benzimidazole derivative and use as a II receptor antagonist 07 Jan, 2025 Expired
US7462626 Compositions for affecting weight loss 20 Jul, 2024 Expired
US8815889 Compositions and methods for increasing insulin sensitivity 20 Jul, 2024 Expired
US8517997 Dispenser for medicaments and method and apparatus for making same 14 May, 2024 Expired
US9119932 Nasal delivery device 23 Apr, 2024 Expired
US11278544 Compositions for affecting weight loss 21 Apr, 2024 Expired
US10130580 Taste-masked pharmaceutical compositions 19 Apr, 2024 Expired
US8327844 Nasal delivery method 03 Oct, 2023 Expired
US8047202 Nasal devices 02 Jul, 2023 Expired
US7070581 Dispenser for medicaments and method and apparatus for making same 23 Jun, 2023 Expired
US6946149 Salt solution for colon cleansing 07 Mar, 2023 Expired
US8048917 Prodrugs of GABA analogs, compositions and uses thereof 06 Nov, 2022 Expired
US6681768 Powder formulation disintegrating system and method for dry powder inhalers 07 Aug, 2022 Expired
US6767901 Ciclesonide contained pharmaceutical composition for application to mucosa 21 Oct, 2020 Expired
US8383611 Ciclesonide containing aqueous pharmaceutical composition 20 Oct, 2020 Expired
US6465463 Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate 08 Sep, 2020 Expired
US6784177 Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate 08 Sep, 2020 Expired
US6750226 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands 05 Sep, 2020 Expired
US7078412 Quinuclidine derivatives and medicinal compositions containing the same 16 Jul, 2020 Expired
US10034867 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020 Expired
US10588895 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020 Expired
US7750023 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020 Expired
US8129405 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020 Expired
US9056100 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020 Expired
US9333195 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020 Expired
US6599498 Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives 08 Mar, 2020 Expired
US7553479 Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof 08 Mar, 2020 Expired
US7871597 Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents 08 Mar, 2020 Expired
US8501158 Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents 08 Mar, 2020 Expired
US8591864 Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents 08 Mar, 2020 Expired
US8926947 Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents 08 Mar, 2020 Expired
US6715485 Nasal delivery device 03 Mar, 2020 Expired
US8555877 Nasal delivery device 03 Mar, 2020 Expired
US6428810 Pharmaceutical formulation comprising omeprazole 03 Nov, 2019 Expired
US6939559 Pharmaceutical composition for application to mucosa 21 Apr, 2019 Expired
US7235247 Pharmaceutical composition for application to mucosa 21 Apr, 2019 Expired
US6120752 Medicinal aerosol products containing formulations of ciclesonide and related steroids 13 May, 2018 Expired
US6264923 Medicinal aerosol formulation of ciclesonide and related compounds 13 May, 2018 Expired
US6080778 Methods for decreasing beta amyloid protein 23 Mar, 2018 Expired
US5872145 Formulation of 5-HT agonist and NSAID for treatment of migraine 14 Feb, 2018 Expired
US6060499 Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs 14 Feb, 2018 Expired
US6586458 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Feb, 2018 Expired
US8022095 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Feb, 2018 Expired
US5916595 HMG co-reductase inhibitor 12 Dec, 2017 Expired
US6485748 Once daily pharmaceutical tablet having a unitary core 12 Dec, 2017 Expired
US5482934 Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions 24 Oct, 2017 Expired
US5872145 Formulation of 5-HT agonist and NSAID for treatment of migraine 14 Aug, 2017 Expired
US6060499 Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs 14 Aug, 2017 Expired
US6586458 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Aug, 2017 Expired
US8022095 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Aug, 2017 Expired
US6006745 Device for delivering an aerosol 28 Dec, 2016 Expired
US5840279 Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments 21 Jun, 2016 Expired
US6071498 Inhaler for powdered medicaments 21 Jun, 2016 Expired
US5900424 Omeprazole magnesium salt form 04 May, 2016 Expired
US5775321 Seal configuration for aerosol canister 07 Jul, 2015 Expired
US5626874 Controlled release pharmaceutical tablet having lenticular form 30 Nov, 2014 Expired
US5690960 Pharmaceutical formulation of omeprazole 25 Nov, 2014 Expired
US5683677 Medicinal aerosol formulations 04 Nov, 2014 Expired
US5958961 Pharmaceutical composition for angiotensin II-mediated diseases 06 Jun, 2014 Expired
US5605674 Medicinal aerosol formulations 25 Feb, 2014 Expired
US5583141 Heterocyclic compounds and their use as angiotensin antagonists 10 Dec, 2013 Expired
US5527814 Use of 2-amino-6-(trifluoromethoxy)benzothiazole for obtaining a medicament for the treatment of amyotrophic lateral sclerosis 18 Jun, 2013 Expired
US6036942 Seal configuration for aerosol canister 30 Apr, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Azurity.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 16 Feb, 2026 US11413277
Payment of Maintenance Fee, 12th Yr, Small Entity 11 Feb, 2026 US8815889 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 09 Feb, 2026 US10039800
Payment of Maintenance Fee, 8th Year, Large Entity 09 Feb, 2026 US10039745
Payment of Maintenance Fee, 12th Year, Large Entity 05 Feb, 2026 US8795725
Payment of Maintenance Fee, 12th Year, Large Entity 15 Jan, 2026 US8778366 (Litigated)
Payment of Maintenance Fee, 4th Yr, Small Entity 12 Jan, 2026 US11382864
Expire Patent 29 Dec, 2025 US8590530
Payment of Maintenance Fee, 4th Year, Large Entity 22 Dec, 2025 US11364230
Recordation of Patent Grant Mailed 16 Dec, 2025 US12491179
Recordation of Patent eGrant 09 Dec, 2025 US12491179
Patent Issue Date Used in PTA Calculation 09 Dec, 2025 US12491179
Mail Patent eGrant Notification 09 Dec, 2025 US12491179
Email Notification 09 Dec, 2025 US12491179
Patent eGrant Notification 09 Dec, 2025 US12491179


Azurity's Drug Patent Litigations

Azurity's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 23, 2009, against patent number US8383611. The petitioner , challenged the validity of this patent, with Atsuhiro Nagano et al as the respondent. Click below to track the latest information on how companies are challenging Azurity's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9463183 July, 2017 Final Written Decision
(07 May, 2018)
Silvergate Pharmaceuticals, Inc. KVK-Tech, Inc. et al.
US7332183 November, 2015 Institution Denied
(06 May, 2016)
POZEN Inc. et al. Graybar Pharmaceuticals, LLC
US8383611 November, 2009 Decision
(22 Feb, 2011)
Atsuhiro Nagano et al


Azurity Drug Patents' Oppositions Filed in EPO

Azurity drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 27, 2005, by Direct-Haler A/S. This opposition was filed on patent number EP00906570A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP08736896A Jun, 2021 Beck Greener LLP Patent maintained as amended
EP13715145A Sep, 2020 ELKINGTON AND FIFE LLP Granted and Under Opposition
EP12172232A Apr, 2019 Generics [UK] Ltd Granted and Under Opposition
EP08763237A Sep, 2017 Ferring B.V. Revoked
EP08763237A Sep, 2017 Generics (UK) Ltd Revoked
EP09719213A May, 2016 Generics (U.K.) Limited Granted and Under Opposition
EP09719213A May, 2016 Hexal AG Granted and Under Opposition
EP04766791A Sep, 2014 Generics [UK] Ltd (trading as Mylan) Patent maintained as amended
EP02744314A Sep, 2008 Breuer, Markus Patent maintained as amended
EP00906570A Sep, 2005 Direct-Haler A/S Opposition rejected


Azurity's Family Patents

Azurity drugs have patent protection in a total of 56 countries. It's US patent count contributes only to 29.2% of its total global patent coverage. 11 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Recent FDA approvals and tentative approvals for Azurity

This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.

Innovator drugs

Includes innovator drug submissions that appear in FDA approval and tentative approval disclosures.

Drug Name Submission class (FDA) Submission Category Submission Date
Edaravone ORIG-1
ⓘ
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Type 3 - New Dosage Form 17 Jul, 2026
Abanta ORIG-1
ⓘ
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
Type 3 - New Dosage Form 29 Jun, 2026
Resniben ORIG-1
ⓘ
Orig = Original submission
Suppl = Supplement submission
Number = submission sequence
- 24 Oct, 2025

Azurity Drug List

Given below is the complete list of Azurity's drugs and the patents protecting them.


1. Altoprev

Altoprev is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6080778 Methods for decreasing beta amyloid protein 23 Mar, 2018
(8 years ago)
Expired
US5916595 HMG co-reductase inhibitor 12 Dec, 2017
(8 years ago)
Expired
US6485748 Once daily pharmaceutical tablet having a unitary core 12 Dec, 2017
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Altoprev's drug page


2. Alvesco

Alvesco is protected by 9 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8371292 Use of ciclesonide for the treatment of respiratory diseases 01 Feb, 2028
(1 year, 5 months from now)
Active
US6120752 Medicinal aerosol products containing formulations of ciclesonide and related steroids 13 May, 2018
(8 years ago)
Expired
US6264923 Medicinal aerosol formulation of ciclesonide and related compounds 13 May, 2018
(8 years ago)
Expired
US5482934 Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions 24 Oct, 2017
(8 years ago)
Expired
US6006745 Device for delivering an aerosol 28 Dec, 2016
(9 years ago)
Expired
US5775321 Seal configuration for aerosol canister 07 Jul, 2015
(11 years ago)
Expired
US5683677 Medicinal aerosol formulations 04 Nov, 2014
(11 years ago)
Expired
US5605674 Medicinal aerosol formulations 25 Feb, 2014
(12 years ago)
Expired
US6036942 Seal configuration for aerosol canister 30 Apr, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Alvesco's drug page


3. Arynta

Arynta is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11576878 Oral solutions comprising lisdexamfetamine salts 30 Aug, 2040
(14 years from now)
Active
US12433859 Oral Solutions Comprising Lisdexamfetamine Salts 16 Apr, 2040
(13 years from now)
Active
US12582620 Oral Solutions Comprising Lisdexamfetamine Salts 16 Apr, 2040
(13 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Arynta's drug page


4. Azmiro

Azmiro is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11311554 Pharmaceutical compositions of testosterone 25 Mar, 2039
(12 years from now)
Active
US11642355 Pharmaceutical compositions of testosterone 25 Mar, 2039
(12 years from now)
Active
US12138271 Pharmaceutical compositions of testosterone 25 Mar, 2039
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Azmiro's drug page


5. Bidil

Bidil is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6465463 Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate 08 Sep, 2020
(5 years ago)
Expired
US6784177 Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate 08 Sep, 2020
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bidil's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Brynovin

Brynovin is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11944621 Oral gliptin compositions and method for preparation thereof 23 Oct, 2040
(14 years from now)
Active
US12295953 Oral gliptin compositions and method for preparation thereof 23 Oct, 2040
(14 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brynovin's drug page


7. Contrave

Contrave is protected by 22 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10231964 Compositions and methods for weight loss in at risk patient populations 02 Jul, 2034
(7 years from now)
Active
US10828294 Compositions and methods for weight loss in at risk patient populations 02 Jul, 2034
(7 years from now)
Active
US10835527 Compositions and methods for reducing major adverse cardiovascular events 02 Jul, 2034
(7 years from now)
Active
US11998542 Compositions and methods for reducing major adverse cardiovascular events 02 Jul, 2034
(7 years from now)
Active
US9633575 Methods of treating overweight and obesity 25 Jun, 2033
(6 years from now)
Active
US10403170 Methods of treating overweight and obesity 05 Jun, 2033
(6 years from now)
Active
US11139056 Methods of treating overweight and obesity 05 Jun, 2033
(6 years from now)
Active
US9248123 Methods of providing weight loss therapy in patients with major depression 13 Jan, 2032
(5 years from now)
Active
US11033543 Methods of providing weight loss therapy in patients with major depression 10 Jan, 2031
(4 years from now)
Active
US8916195 Sustained release formulation of naltrexone 02 Feb, 2030
(3 years from now)
Active
US11324741 Methods for treating visceral fat conditions 29 May, 2029
(2 years from now)
Active
US8088786 Layered pharmaceutical formulations 03 Feb, 2029
(2 years from now)
Active
US10307376 Methods for administering weight loss medications 08 Nov, 2027
(1 year, 2 months from now)
Active
US12048769 Methods for administering weight loss medications 08 Nov, 2027
(1 year, 2 months from now)
Active
US8318788 Layered pharmaceutical formulations 08 Nov, 2027
(1 year, 2 months from now)
Active
US8722085 Methods for administering weight loss medications 08 Nov, 2027
(1 year, 2 months from now)
Active
US9125868 Methods for administering weight loss medications 08 Nov, 2027
(1 year, 2 months from now)
Active
US9107837 Sustained release formulation of naltrexone 04 Jun, 2027
(9 months from now)
Active
US7375111 Compositions for affecting weight loss 26 Mar, 2025
(1 year, 4 months ago)
Expired
US7462626 Compositions for affecting weight loss 20 Jul, 2024
(2 years ago)
Expired
US8815889 Compositions and methods for increasing insulin sensitivity 20 Jul, 2024
(2 years ago)
Expired
US11278544 Compositions for affecting weight loss 21 Apr, 2024
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Contrave's drug page


8. Danziten

Danziten is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10874671 Pharmaceutical compositions of nilotinib 18 Feb, 2040
(13 years from now)
Active
US11793809 Pharmaceutical compositions of nilotinib 18 Feb, 2040
(13 years from now)
Active
US12403140 Pharmaceutical Compositions Of Nilotinib 18 Feb, 2040
(13 years from now)
Active
US12629369 Pharmaceutical Compositions Of Nilotinib 18 Feb, 2040
(13 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Danziten's drug page


9. Duaklir Pressair

Duaklir Pressair is protected by 12 patents, out of which 9 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10085974 Dosage and formulation 13 Mar, 2029
(2 years from now)
Active
US11000517 Dosage and formulation 13 Mar, 2029
(2 years from now)
Active
US8051851 Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler 22 Apr, 2027
(8 months from now)
Active
USRE46417 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands 10 Feb, 2025
(1 year, 6 months ago)
Expired
US6681768 Powder formulation disintegrating system and method for dry powder inhalers 07 Aug, 2022
(4 years ago)
Expired
US10034867 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020
(6 years ago)
Expired
US10588895 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020
(6 years ago)
Expired
US7078412 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020
(6 years ago)
Expired
US7750023 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020
(6 years ago)
Expired
US8129405 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020
(6 years ago)
Expired
US9056100 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020
(6 years ago)
Expired
US9333195 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Duaklir Pressair's drug page


10. Edarbi

Edarbi is protected by 5 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9066936 Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent 26 Mar, 2028
(1 year, 7 months from now)
Active
US7157584 Benzimidazole derivative and use thereof 22 May, 2025
(1 year, 2 months ago)
Expired
US7572920 Benzimidazole derivative and use as a II receptor antagonist 07 Jan, 2025
(1 year, 7 months ago)
Expired
US5958961 Pharmaceutical composition for angiotensin II-mediated diseases 06 Jun, 2014
(12 years ago)
Expired
US5583141 Heterocyclic compounds and their use as angiotensin antagonists 10 Dec, 2013
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Edarbi's drug page


11. Edarbyclor

Edarbyclor is protected by 6 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9387249 Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone 01 Jul, 2031
(4 years from now)
Active
US9169238 Solid pharmaceutical composition 04 Feb, 2030
(3 years from now)
Active
US9066936 Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent 26 Mar, 2028
(1 year, 7 months from now)
Active
US7157584 Benzimidazole derivative and use thereof 22 May, 2025
(1 year, 2 months ago)
Expired
US7572920 Benzimidazole derivative and use as a II receptor antagonist 07 Jan, 2025
(1 year, 7 months ago)
Expired
US5583141 Heterocyclic compounds and their use as angiotensin antagonists 10 Dec, 2013
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Edarbyclor's drug page


12. Epaned

Epaned is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10039745 Enalapril formulations 25 Mar, 2036
(9 years from now)
Active
US10154987 Enalapril formulations 25 Mar, 2036
(9 years from now)
Active
US10772868 Enalapril formulations 25 Mar, 2036
(9 years from now)
Active
US10786482 Enalapril formulations 25 Mar, 2036
(9 years from now)
Active
US11040023 Enalapril formulations 25 Mar, 2036
(9 years from now)
Active
US11141405 Enalapril formulations 25 Mar, 2036
(9 years from now)
Active
US11173141 Enalapril formulations 25 Mar, 2036
(9 years from now)
Active
US9669008 Enalapril formulations 25 Mar, 2036
(9 years from now)
Active
US9808442 Enalapril formulations 25 Mar, 2036
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epaned's drug page


13. Epaned Kit

Epaned Kit is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8568747 Enalapril compositions 06 Nov, 2032
(6 years from now)
Active
US8778366 Enalapril compositions 06 Nov, 2032
(6 years from now)
Active
US9855214 Enalapril compositions 06 Nov, 2032
(6 years from now)
Active
US9968553 Enalapril compositions 06 Nov, 2032
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epaned Kit's drug page


14. Eprontia

Eprontia is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11433046 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
(14 years from now)
Active
US11633374 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
(14 years from now)
Active
US11826343 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
(14 years from now)
Active
US11911362 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
(14 years from now)
Active
US12290503 Compositions and methods for treating epilepsy, seizures and other conditions 21 Aug, 2040
(14 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eprontia's drug page


15. Evekeo Odt

Evekeo Odt is protected by 4 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10441554 Oral amphetamine composition 10 Mar, 2037
(10 years from now)
Active
US11160772 Oral amphetamine composition 10 Mar, 2037
(10 years from now)
Active
US11896562 Oral amphetamine composition 10 Mar, 2037
(10 years from now)
Active
US10130580 Taste-masked pharmaceutical compositions 19 Apr, 2024
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Evekeo Odt's drug page


16. Feraheme

Feraheme is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6599498 Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives 08 Mar, 2020
(6 years ago)
Expired
US7553479 Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof 08 Mar, 2020
(6 years ago)
Expired
US7871597 Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents 08 Mar, 2020
(6 years ago)
Expired
US8501158 Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents 08 Mar, 2020
(6 years ago)
Expired
US8591864 Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents 08 Mar, 2020
(6 years ago)
Expired
US8926947 Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents 08 Mar, 2020
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Feraheme's drug page


17. Firvanq Kit

Firvanq Kit is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10493028 Composition and method for vancomycin oral liquid 13 Mar, 2035
(8 years from now)
Active
US10688046 Composition and method for vancomycin oral liquid 13 Mar, 2035
(8 years from now)
Active
US10959946 Composition and method for vancomycin oral liquid 13 Mar, 2035
(8 years from now)
Active
US10959947 Composition and method for vancomycin oral liquid 13 Mar, 2035
(8 years from now)
Active
US10959948 Composition and method for vancomycin oral liquid 13 Mar, 2035
(8 years from now)
Active
US10959949 Composition and method for vancomycin oral liquid 13 Mar, 2035
(8 years from now)
Active
US11638692 Composition and method for vancomycin oral liquid 13 Mar, 2035
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Firvanq Kit's drug page


18. Fleqsuvy

Fleqsuvy is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11324696 Suspensions and diluents for metronidazole and baclofen 29 Sep, 2037
(11 years from now)
Active
US11446246 Suspensions and diluents for metronidazole and baclofen 08 Sep, 2037
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fleqsuvy's drug page


19. Horizant

Horizant is protected by 6 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8795725 GABA analog prodrug sustained release oral dosage forms 10 Jun, 2029
(2 years from now)
Active
US8026279 Crystalline form of γ-aminobutyric acid analog 10 Nov, 2026
(2 months from now)
Active
US8114909 Treating or preventing restless legs syndrome using prodrugs of GABA analogs 11 Apr, 2026
(4 months ago)
Expired
US6818787 Prodrugs of GABA analogs, compositions and uses thereof 06 Apr, 2025
(1 year, 4 months ago)
Expired
US8686034 Crystalline form of γ-aminobutyric acid analog 24 Jan, 2025
(1 year, 6 months ago)
Expired
US8048917 Prodrugs of GABA analogs, compositions and uses thereof 06 Nov, 2022
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Horizant's drug page


20. Javadin

Javadin is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12233049 Stable Pharmaceutical Compositions Of Clonidine 15 Jul, 2042
(15 years from now)
Active
US12440474 Stable Pharmaceutical Compositions Of Clonidine 15 Jul, 2042
(15 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Javadin's drug page


21. Katerzia

Katerzia is protected by 13 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10799453 Amlodipine formulations 11 Apr, 2039
(12 years from now)
Active
US10695329 Amlodipine formulations 16 Oct, 2037
(11 years from now)
Active
US10894039 Amlodipine formulations 06 Oct, 2037
(11 years from now)
Active
US10952998 Amlodipine formulations 06 Oct, 2037
(11 years from now)
Active
US10959991 Amlodipine formulations 06 Oct, 2037
(11 years from now)
Active
US11364230 Amlodipine formulations 06 Oct, 2037
(11 years from now)
Active
US11471409 Amlodipine formulations 06 Oct, 2037
(11 years from now)
Active
US11484498 Amlodipine formulations 06 Oct, 2037
(11 years from now)
Active
US11701326 Amlodipine formulations 06 Oct, 2037
(11 years from now)
Active
US11918685 Amlodipine formulations 06 Oct, 2037
(11 years from now)
Active
US12053461 Amlodipine formulations 06 Oct, 2037
(11 years from now)
Active
US12336984 Amlodipine formulations 06 Oct, 2037
(11 years from now)
Active
US12383498 Amlodipine Formulations 06 Oct, 2037
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Katerzia's drug page


22. Konvomep

Konvomep is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11771686 Compositions and kits for omeprazole suspension 01 Mar, 2040
(13 years from now)
Active
US10751333 Compositions and kits for omeprazole suspension 16 Jul, 2039
(12 years from now)
Active
US11103492 Compositions and kits for omeprazole suspension 16 Jul, 2039
(12 years from now)
Active
US11633478 Compositions and kits for Omeprazole suspension 16 Jul, 2039
(12 years from now)
Active
US11911473 Compositions and kits for omeprazole suspension 16 Jul, 2039
(12 years from now)
Active
US12042539 Compositions and kits for Omeprazole suspension 16 Jul, 2039
(12 years from now)
Active
US12329752 Compositions and kits for omeprazole suspension 16 Jul, 2039
(12 years from now)
Active
US12440566 Compositions And Kits For Omeprazole Suspension 16 Jul, 2039
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Konvomep's drug page


23. Myhibbin

Myhibbin is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11931455 Pharmaceutical suspension for oral dosage 16 Aug, 2039
(13 years from now)
Active
US12097284 Mycophenolate oral suspension 16 Aug, 2039
(13 years from now)
Active
US12097285 Mycophenolate oral suspension 16 Aug, 2039
(13 years from now)
Active
US12194143 Mycophenolate oral suspension 16 Aug, 2039
(13 years from now)
Active
US12226526 Mycophenolate oral suspension 16 Aug, 2039
(13 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myhibbin's drug page


24. Nymalize

Nymalize is protected by 10 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10342787 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
(11 years from now)
Active
US10576070 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
(11 years from now)
Active
US11207306 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
(11 years from now)
Active
US11413277 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
(11 years from now)
Active
US11517563 Liquid nimodipine compositions 16 Apr, 2038
(11 years from now)
Active
US11759457 Liquid nimodipine compositions 16 Apr, 2038
(11 years from now)
Active
US11806338 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
(11 years from now)
Active
US12186308 Non-aqueous liquid nimodipine compositions 16 Apr, 2038
(11 years from now)
Active
US8517997 Dispenser for medicaments and method and apparatus for making same 14 May, 2024
(2 years ago)
Expired
US7070581 Dispenser for medicaments and method and apparatus for making same 23 Jun, 2023
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nymalize's drug page


25. Omnaris

Omnaris is protected by 6 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8371292 Use of ciclesonide for the treatment of respiratory diseases 01 Feb, 2028
(1 year, 5 months from now)
Active
US6767901 Ciclesonide contained pharmaceutical composition for application to mucosa 21 Oct, 2020
(5 years ago)
Expired
US8383611 Ciclesonide containing aqueous pharmaceutical composition 20 Oct, 2020
(5 years ago)
Expired
US6939559 Pharmaceutical composition for application to mucosa 21 Apr, 2019
(7 years ago)
Expired
US7235247 Pharmaceutical composition for application to mucosa 21 Apr, 2019
(7 years ago)
Expired
US5482934 Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions 24 Oct, 2017
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Omnaris's drug page


26. Onzetra Xsail

Onzetra Xsail is protected by 20 patents, out of which 9 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10076614 Nasal delivery devices 20 Oct, 2034
(8 years from now)
Active
US10478574 Nasal administration 04 Nov, 2033
(7 years from now)
Active
US8978647 Nasal delivery 06 Dec, 2030
(4 years from now)
Active
US9649456 Nasal administration 21 Oct, 2030
(4 years from now)
Active
US8899229 Powder delivery devices 18 Aug, 2030
(4 years from now)
Active
US8550073 Nasal delivery 22 Oct, 2029
(3 years from now)
Active
US10076615 Nasal delivery 30 Jul, 2029
(2 years from now)
Active
US10722667 Nasal administration 30 Dec, 2028
(2 years from now)
Active
US8875704 Nasal administration 07 Apr, 2028
(1 year, 7 months from now)
Active
US10398859 Nasal delivery devices 19 Dec, 2027
(1 year, 4 months from now)
Active
US10124132 Nasal delivery 06 Mar, 2027
(6 months from now)
Active
US11571531 Powder delivery devices 23 Feb, 2026
(5 months ago)
Expired
US8590530 Nasal delivery devices 15 Sep, 2025
(11 months ago)
Expired
US9108015 Nasal delivery devices 15 Sep, 2025
(11 months ago)
Expired
US7975690 Nasal devices 18 Aug, 2025
(a year ago)
Expired
US9119932 Nasal delivery device 23 Apr, 2024
(2 years ago)
Expired
US8327844 Nasal delivery method 03 Oct, 2023
(2 years ago)
Expired
US8047202 Nasal devices 02 Jul, 2023
(3 years ago)
Expired
US6715485 Nasal delivery device 03 Mar, 2020
(6 years ago)
Expired
US8555877 Nasal delivery device 03 Mar, 2020
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onzetra Xsail's drug page


27. Prevduo

Prevduo is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10456354 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate 25 Oct, 2038
(12 years from now)
Active
US11110054 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate 25 Oct, 2038
(12 years from now)
Active
US11938217 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate 25 Oct, 2038
(12 years from now)
Active
US12151020 Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate 25 Oct, 2038
(12 years from now)
Active
US12383491 Ready-To-Use Injectable Pharmaceutical Compositions Comprising Neostigmine And Glycopyrrolate 25 Oct, 2038
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prevduo's drug page


28. Prilosec

Prilosec is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6428810 Pharmaceutical formulation comprising omeprazole 03 Nov, 2019
(6 years ago)
Expired
US5900424 Omeprazole magnesium salt form 04 May, 2016
(10 years ago)
Expired
US5690960 Pharmaceutical formulation of omeprazole 25 Nov, 2014
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prilosec's drug page


29. Qbrelis

Qbrelis is protected by 12 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10039800 Lisinopril formulations 06 Nov, 2035
(9 years from now)
Active
US10265370 Lisinopril formulations 06 Nov, 2035
(9 years from now)
Active
US10406199 Lisinopril formulations 06 Nov, 2035
(9 years from now)
Active
US10940177 Lisinopril formulations 06 Nov, 2035
(9 years from now)
Active
US11179434 Lisinopril formulations 06 Nov, 2035
(9 years from now)
Active
US11771733 Lisinopril formulations 06 Nov, 2035
(9 years from now)
Active
US12128083 Lisinopril formulations 06 Nov, 2035
(9 years from now)
Active
US12186360 Lisinopril formulations 06 Nov, 2035
(9 years from now)
Active
US12433931 Lisinopril Formulations 06 Nov, 2035
(9 years from now)
Active
US9463183 Lisinopril formulations 06 Nov, 2035
(9 years from now)
Active
US9616096 Lisinopril formulations 06 Nov, 2035
(9 years from now)
Active
US9814751 Lisinopril formulations 06 Nov, 2035
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qbrelis's drug page


30. Rilutek

Rilutek is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5527814 Use of 2-amino-6-(trifluoromethoxy)benzothiazole for obtaining a medicament for the treatment of amyotrophic lateral sclerosis 18 Jun, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rilutek's drug page


31. Sotylize

Sotylize is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9724297 Sotalol compositions and uses of the same 31 Aug, 2035
(9 years from now)
Active
US11850222 Sotalol compositions and uses of the same 19 Nov, 2034
(8 years from now)
Active
US10206895 Sotalol compositions and uses of the same 01 Apr, 2034
(7 years from now)
Active
US11013703 Sotalol compositions and uses of the same 01 Apr, 2034
(7 years from now)
Active
US12290495 Sotalol compositions and uses of the same 01 Apr, 2034
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sotylize's drug page


32. Suflave

Suflave is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12290529 Methods of administering safe colon cleansing compositions 02 Aug, 2044
(17 years from now)
Active
US12239659 Methods of administering safe colon cleansing compositions 14 Jun, 2044
(17 years from now)
Active
US12433914 Methods Of Administering Safe Colon Cleansing Compositions 14 Jun, 2044
(17 years from now)
Active
US12594298 Methods Of Administering Safe Colon Cleansing Compositions 14 Jun, 2044
(17 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Suflave's drug page


33. Sular

Sular is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5626874 Controlled release pharmaceutical tablet having lenticular form 30 Nov, 2014
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sular's drug page


34. Suprep Bowel Prep Kit

Suprep Bowel Prep Kit is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6946149 Salt solution for colon cleansing 07 Mar, 2023
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Suprep Bowel Prep Kit's drug page


35. Sutab

Sutab is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10143656 Solid oral sulfate salt formulations for cleaning a colon and methods of using same 04 Aug, 2037
(10 years from now)
Active
US11033498 Solid oral sulfate salt formulations for cleaning a colon and methods of using same 04 Aug, 2037
(10 years from now)
Active
US11382864 Solid oral sulfate salt formulations for cleansing a colon and methods of using same 04 Aug, 2037
(10 years from now)
Active
US11638697 Solid oral sulfate salt formulations for cleaning a colon and methods of using same 04 Aug, 2037
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sutab's drug page


36. Treximet

Treximet is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7332183
(Pediatric)
Multilayer dosage forms containing NSAIDs and triptans 02 Apr, 2026
(4 months ago)
Expired
US7332183 Multilayer dosage forms containing NSAIDs and triptans 02 Oct, 2025
(10 months ago)
Expired
US5872145
(Pediatric)
Formulation of 5-HT agonist and NSAID for treatment of migraine 14 Feb, 2018
(8 years ago)
Expired
US6060499
(Pediatric)
Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs 14 Feb, 2018
(8 years ago)
Expired
US6586458
(Pediatric)
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Feb, 2018
(8 years ago)
Expired
US8022095
(Pediatric)
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Feb, 2018
(8 years ago)
Expired
US5872145 Formulation of 5-HT agonist and NSAID for treatment of migraine 14 Aug, 2017
(9 years ago)
Expired
US6060499 Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs 14 Aug, 2017
(9 years ago)
Expired
US6586458 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Aug, 2017
(9 years ago)
Expired
US8022095 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs 14 Aug, 2017
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Treximet's drug page


37. Triptodur Kit

Triptodur Kit is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10166181 Slow release pharmaceutical composition made of microgranules 30 Jun, 2029
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Triptodur Kit's drug page


38. Tudorza Pressair

Tudorza Pressair is protected by 13 patents, out of which 10 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10085974 Dosage and formulation 13 Mar, 2029
(2 years from now)
Active
US11000517 Dosage and formulation 13 Mar, 2029
(2 years from now)
Active
US8051851 Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler 22 Apr, 2027
(8 months from now)
Active
USRE46417 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands 10 Feb, 2025
(1 year, 6 months ago)
Expired
US6681768 Powder formulation disintegrating system and method for dry powder inhalers 07 Aug, 2022
(4 years ago)
Expired
US6750226 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands 05 Sep, 2020
(5 years ago)
Expired
US7078412 Quinuclidine derivatives and medicinal compositions containing the same 16 Jul, 2020
(6 years ago)
Expired
US10034867 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020
(6 years ago)
Expired
US10588895 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020
(6 years ago)
Expired
US9056100 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020
(6 years ago)
Expired
US9333195 Quinuclidine derivatives and medicinal compositions containing the same 07 Jul, 2020
(6 years ago)
Expired
US5840279 Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments 21 Jun, 2016
(10 years ago)
Expired
US6071498 Inhaler for powdered medicaments 21 Jun, 2016
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tudorza Pressair's drug page


39. Vivimusta

Vivimusta is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11707450 29 Jul, 2042
(15 years from now)
Active
US11844784 Stable pharmaceutical compositions of bendamustine 29 Jul, 2042
(15 years from now)
Active
US12208086 Stable pharmaceutical compositions of bendamustine 29 Jul, 2042
(15 years from now)
Active
US12419867 Stable Pharmaceutical Compositions Of Bendamustine 29 Jul, 2042
(15 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vivimusta's drug page


40. Widaplik

Widaplik is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10322117 Compositions for the treatment of hypertension 23 Jan, 2038
(11 years from now)
Active
US10799487 Compositions for the treatment of hypertension 23 Jan, 2038
(11 years from now)
Active
US12465599 Compositions For The Treatment Of Hypertension 23 Jan, 2038
(11 years from now)
Active
US12673047 Compositions For The Treatment Of Hypertension 23 Jan, 2038
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Widaplik's drug page


41. Xatmep

Xatmep is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10231927 Methotrexate composition 02 Jan, 2033
(6 years from now)
Active
US10610485 Methotrexate composition 02 Jan, 2033
(6 years from now)
Active
US11116724 Methotrexate composition 02 Jan, 2033
(6 years from now)
Active
US11969503 Methotrexate composition 02 Jan, 2033
(6 years from now)
Active
US12396947 Methotrexate Composition 02 Jan, 2033
(6 years from now)
Active
US9259427 Methotrexate composition 02 Jan, 2033
(6 years from now)
Active
US9855215 Methotrexate composition 02 Jan, 2033
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xatmep's drug page


42. Xifyrm

Xifyrm is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12263176 Pharmaceutical liquid compositions of meloxicam 31 Jul, 2041
(14 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xifyrm's drug page


43. Zetonna

Zetonna is protected by 9 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8371292 Use of ciclesonide for the treatment of respiratory diseases 01 Feb, 2028
(1 year, 5 months from now)
Active
US6120752 Medicinal aerosol products containing formulations of ciclesonide and related steroids 13 May, 2018
(8 years ago)
Expired
US6264923 Medicinal aerosol formulation of ciclesonide and related compounds 13 May, 2018
(8 years ago)
Expired
US5482934 Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions 24 Oct, 2017
(8 years ago)
Expired
US6006745 Device for delivering an aerosol 28 Dec, 2016
(9 years ago)
Expired
US5775321 Seal configuration for aerosol canister 07 Jul, 2015
(11 years ago)
Expired
US5683677 Medicinal aerosol formulations 04 Nov, 2014
(11 years ago)
Expired
US5605674 Medicinal aerosol formulations 25 Feb, 2014
(12 years ago)
Expired
US6036942 Seal configuration for aerosol canister 30 Apr, 2013
(13 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zetonna's drug page


44. Zonisade

Zonisade is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11478456 Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof 18 Aug, 2038
(12 years from now)
Active
US11529333 Oral pharmaceutical composition comprising zonisamide and process of preparation thereof 18 Aug, 2038
(12 years from now)
Active
US12491179 Oral Pharmaceutical Composition Comprising Zonisamide And Process Of Preparation Thereof 18 Aug, 2038
(12 years from now)
Active
US12685723 18 Aug, 2038
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zonisade's drug page